Skip to content

XOMA Corporation XOMA Return on equity

Return on equity at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
17.1%+11.5pp
Royalty Pharma logo
Royalty PharmaRPRX
8.4%-2.7pp
Theravance Biopharma logo
Theravance BiopharmaTBPH
50.2%+36.2pp
Innoviva, Inc. logo
Innoviva, Inc.INVA
29.1%
Zymeworks logo
ZymeworksZYME
-42%+29.2pp
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-325.6%+36.9pp

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$745.16M+159%
Enterprise value$784.29M+151%
P/E22×
P/S15.4×+8.6×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Calculated from XOMA Corporation’s reported figures.

Based on trailing twelve months.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's return on equity?
XOMA Corporation (XOMA) reported return on equity of 38.1% in Q1 2026.
How has XOMA Corporation's return on equity changed year-over-year?
XOMA Corporation's return on equity increased by 1212.4% year-over-year, from -3.4% to 38.1%.
What is the long-term trend for XOMA Corporation's return on equity?
Over 5 years (2020 to 2025), XOMA Corporation's return on equity has grown at a 16.4% compound annual growth rate (CAGR), from 20.4% to 43.5%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.